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Shalet, S. M., Beardwell, C. G., Morris Jones, P. H., and Pearson, D. (1976) . Archives of Disease in Childhood, 51, 489. Growth hormone deficiency after treatment of acute leukaemia in children. Growth hormone (GH) secretion was studied in 15 children at various times after treatment for acute lymphatic leukaemia. Impaired GH responses both to hypoglycaemia and to Bovril were found in 4 children. 13 of the children had been given prophylactic cranial irradiation of either 2500 rads in 10 fractions or 2400 rads in 20 fractions. The reduction in GH responses in those given the former dose was highly significant compared with the reduction in those given the latter dose. However, other differences between the two groups included the length of time since cranial irradiation and the chemotherapy used. The main cause of the GH deficiency is not yet clear, but we conclude that it may occur in children treated successfully for acute lymphatic leukaemia.
Short stature is a recognized sequel to the treatment of brain tumours in children (Bamford et al., 1976; Onoyama et al., 1975) . Growth hormone (GH) deficiency seems to be common in such patients (Shalet et al., 1975) and may well be a major aetiological factor. Children with brain tumours are treated by a variety of methods, including chemotherapy, neurosurgery, and radiotherapy. The cause of GH deficiency has not yet been elucidated but radiotherapy is thought to play an important role. The recently improved prognosis in acute lymphatic leukaemia in childhood is partly owed to the introduction of prophylactic cranial irradiation (Aur et al., 1972) . It therefore seemed worthwhile to see whether this treatment affected GH secretion.
Patients and methods Fifteen prepubertal children who had been treated for acute lymphatic leukaemia were studied. Only one of the 15 was still being treated with a cytotoxic agent and all had been in complete clinical remission for at least three years. Clinical details of the 15 patients are shown in Table I .
The drugs given in the UKALL I protocol are prednisolone, vincristine, 6-mercaptopurine, asparaginase, cytosine arabinoside, and methotrexate. The only additional chemotherapeutic agent given in UKALL II is cyclophosphamide. In the Memphis Total Therapy V protocol the drugs are prednisolone, vincristine, methotrexate, 6-mercaptopurine, and cyclophosphamide, while the Concord protocol includes all these except cyclophosphamide but adds asparaginase.
The object and exact nature of the studies were explained to the children and their parents and their consent obtained before investigations were started. Standing and sitting heights were measured with % stadiometer. Bone age was estimated using the atlas of Greulich and Pyle (1959) . Plain skuU x-ray films were taken to estimate pituitary fossa size in order to exclude coincidental disease affecting the hypothalamic-pituitary region.
An insulin tolerance test was carried out on all the children after an ovemight fast. Soluble insulin (0-2 units/kg) was given intravenously after the basal blood samples had been taken. Venous blood for the estimation of GH, cortisol, and glucose was withdrawn at 30-minute intervals over a period of 2 hours. Estimations of serum thyroid-stimulating hormones (TSH), thyroxine (T4), and tri-iodothyronine (T3) were made on basal blood samples. GH secretion after an oral dose of Bovril (Jackson, Grant, and Clayton, 1968 ) was also measured.
Plasma cortisol was measured fluorimetrically (Mattingly, 1962) and blood glucose by the neocuproine method (Brown, 1961) . Serum TSH, T3, T4 and GH were measured by double antibody radioimmunoassay, MRC standard 68/38 was used in the TSH assay and 66/217 in the GH assay. Results Adequate hypoglycaemia, as defined by the presence of hypoglycaemic symptoms and a blood sugar nadir of 2 2 mmol/l or less, was obtained in each child. Data obtained in our laboratory show that normal children and adults attain a GH peak of 20 mU/l after such a stimulus (Shalet et al., 1975) . The peak GH responses to both hypoglycaemia and Bovril are shown in Table II . 6 of the children showed an impaired GH response to an insulin tolerance test (ITT), while in 7 the GH response to Bovril was inadequatc-that is <20 mU/l.
It is generally accepted that children with normal GH production may fail to respond to a single test (Raiti, Davis, and Blizzard, 1967; Weldon et al., 1973) and that GH deficiency should be presumed only if failure of response is seen in at least two different tests. By this criterion only 4 out of the 15 children can be assumed to be GH deficient.
In Cases 1 to 8 2500 rads had been delivered to the midplane of the cranium in 14 days (10 fractions), whereas in Cases 9 to 13 a dose of 2400 rads had been given in 27 days (20 fractions). All the patients had received homogeneous irradiation throughout the cranium and there were few deviations from the planned duration of treatment. In order to compare the effects of these two radiation regimens the children were divided into two LE II U test showed a highly significant difference (P = 0 -006). Standing and sitting heights were estimated using standard charts (Tanner, Whitehouse, and Takaishi, 1966) , and the centile height at the time of study of each child is shown in Table II .
Thirteen of the patients had received spinal irradiation, and at least 5 had overt skeletal disproportion with impaired spinal growth. In 2 out of the 4 patients (Cases 1, 7) with GH deficiency the bone age was consistent with chronological age. In the other cases the bone age was retarded by 16 months (Case 2) and 54 months (Case 4) respectively. Fig. 1 shows the growth chart in Case 4, the only girl with GH deficiency. During the period of chemotherapy the growth velocity fell away from the 3rd centile and appeared to recover a little over the year after the cessation of all therapy. However, over the last 1 * 4 years the growth velocity fell away again, perhaps related to the GH deficiency. Fig. 2 shows the growth chart of Cases 1, 2, and 7, the 3 boys with GH deficiency. During the latter half of chemotherapy the growth velocity fell away in each and when the drugs were stopped there were no pronounced changes. However, the longest period off all therapy for these subjects was 2 years (Case 7).
The peak cortisol response to insulin hypoglycaemia was normal in each child and none were hypothyroid, either clinically or biochemically. X-ray examination of the pituitary fossa showed no abnormality. Discussion Reports of the effect of long-term antileukaemic therapy on growth are conflicting. Sundermann Pinkel (1971) , however, described 3 children whose growth rates decreased while they were receiving treatment. After chemotherapy was discontinued their height increments increased, so that within three years their heights were at or above the initial centiles. In 2 other children linear growth rate was reduced during therapy, and this continued after treatment was stopped. The children in Pinkel's study (1971) received cranial irradiation plus more intensive chemotherapy than those described by Sundermann and Pearson (1969) .
Most ofour 15 children showed a decrease in linear growth, particularly towards the latter part of their chemotherapy. This may have been due to the disease, the intensive chemotherapy, or the spinal irradiation. The 3 boys with impaired GH responses showed no evidence of any pronounced change in their growth rates when the chemotherapy ceased. The only girl with impaired GH responses had a growth rate which, a year after the chemotherapy stopped, continued to decline away from the 3rd centile, as is typically seen in GH deficiency. Insufficient time has elapsed as yet to enable us to determine whether growth rates in the children with apparent GH deficiency differ from those of the children whose GH responses appear to be normal, so that we cannot yet be certain whether the impaired GH responses are biologically significant.
We have previously shown (Shalet et al., 1975 ) that in children receiving treatment for intracranial tumours there is a progressive decline in the GH response to hypoglycaemia with increasing time after initial treatment. This makes it difficult to determine the exact time at which GH production falls below normal. However, in two of the boys (Cases 1, 7) with impaired GH responses the lack of bone age retardation suggests that it is of recent occurrence. In the same group of children treated for intracranial tumours we found that the median peak GH level after hypoglycaemia was significantly blunted within 3 months of starting therapy compared to that of normal children, though still within the normal range. Dacou-Voutetakis et al. (1975) reported a significant fall in mean GH concentrations after three weeks of cranial irradiation (2400 rad) in children with acute leukaemia.
In our group there was a difference in the GH response according to the cranial irradiation regimen. Children who received 2500 rads in 10 fractions showed a highly significant reduction in GH response compared to those who received 2400 rads in 20 fractions. However, although the former group received a higher effective biological dose of radiation it cannot necessarily be assumed that this was the only cause of the greater reduction in GH output. Children receiving the higher dose were all treated before the others and their lower GH responses could, therefore, simply reflect the length of time elapsed since treatment was completed. Furthermore, the chemotherapeutic regimens in the two groups, though similar, had certain subtle differences.
Whatever is the major factor in the aetiology of the reduced GH production probably an increasing number of children with acute lymphatic leukaemia will be at risk of developing GH deficiency over the next few years. With the great advances made in the prognosis of children with acute lymphatic leukaemia much more attention has been focused on the quality of their survival. This must include the detection and treatment of GH deficiency when appropriate.
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